Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Sinobiomed has announced that it is launching the Phase II clinical trial of its patented malaria vaccine candidate, PfCP2.9, in epidemic areas in third quarter 2008.
Subscribe to our email newsletter
Sinobiomed will conduct the trial in collaboration with Mahidol University in Bangkok, Thailand. The study site is located in Thailand’s Ratchaburi Province, approximately 200km from Bangkok near the Myanmar border. Currently the vaccine trial center is sponsoring Phase II trials for an HIV vaccine and a dengue fever vaccine. Preparations for the Phase II trial of PfCP2.9 are now underway.
In January 2008, Sinobiomed was approved to receive grants from government funding of $1.24 million to undertake the Phase II clinical trial of its recombinant malaria vaccine in epidemic areas. Sinobiomed has exclusive usage rights to the PfCP2.9 vaccine, which was developed by SMMU. PfCP2.9 has been granted Chinese, US, EU and Australian patents.